$RGLS
Regulus Therapeutics Inc.

2012 Q4 Form 10-Q Financial Statement

#000119312512475602 Filed on November 19, 2012

View on sec.gov

Income Statement

Concept 2012 Q4 2012 Q3 2011 Q4
Revenue $3.238M $2.809M $3.363M
YoY Change -3.72% -26.25%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.930M $1.090M $770.0K
YoY Change 150.65% 19.78%
% of Gross Profit
Research & Development $5.610M $5.248M $4.470M
YoY Change 25.5% 35.43%
% of Gross Profit
Depreciation & Amortization $280.0K $260.0K $250.0K
YoY Change 12.0% 13.04%
% of Gross Profit
Operating Expenses $7.541M $6.341M $5.238M
YoY Change 43.97% 32.6%
Operating Profit -$3.532M
YoY Change 263.0%
Interest Expense $80.00K $110.0K -$60.00K
YoY Change -233.33% 13.4%
% of Operating Profit
Other Income/Expense, Net $0.00 $0.00
YoY Change -100.0%
Pretax Income -$6.860M -$5.691M -$1.940M
YoY Change 253.61% 446.69%
Income Tax $20.00K -$6.000K $80.00K
% Of Pretax Income
Net Earnings -$6.876M -$5.685M -$2.015M
YoY Change 241.24% 444.02%
Net Earnings / Revenue -212.35% -202.39% -59.92%
Basic Earnings Per Share -$15.98
Diluted Earnings Per Share -$10.12M -$15.98 -$33.67M
COMMON SHARES
Basic Shares Outstanding 35.83M shares 355.7M shares
Diluted Shares Outstanding 355.7M shares

Balance Sheet

Concept 2012 Q4 2012 Q3 2011 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $98.10M $30.90M $38.10M
YoY Change 157.48%
Cash & Equivalents $40.55M $17.43M $9.175M
Short-Term Investments $57.50M $13.50M $29.00M
Other Short-Term Assets $800.0K $500.0K $500.0K
YoY Change 60.0%
Inventory
Prepaid Expenses
Receivables $3.000M $0.00
Other Receivables $0.00 $0.00
Total Short-Term Assets $98.93M $34.36M $38.67M
YoY Change 155.86%
LONG-TERM ASSETS
Property, Plant & Equipment $3.310M $3.144M $3.110M
YoY Change 6.43%
Goodwill
YoY Change
Intangibles $1.154M $1.124M $980.0K
YoY Change 17.76%
Long-Term Investments
YoY Change
Other Assets $125.0K $2.096M $125.0K
YoY Change 0.0%
Total Long-Term Assets $4.589M $6.364M $4.215M
YoY Change 8.87%
TOTAL ASSETS
Total Short-Term Assets $98.93M $34.36M $38.67M
Total Long-Term Assets $4.589M $6.364M $4.215M
Total Assets $103.5M $40.72M $42.88M
YoY Change 141.41%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $311.0K $649.0K $501.0K
YoY Change -37.92%
Accrued Expenses $658.0K $2.100M $943.0K
YoY Change -30.22%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $100.0K $400.0K
YoY Change
Total Short-Term Liabilities $12.77M $13.41M $12.85M
YoY Change -0.64%
LONG-TERM LIABILITIES
Long-Term Debt $10.10M $17.40M $10.40M
YoY Change -2.88%
Other Long-Term Liabilities $767.0K $18.30M $1.847M
YoY Change -58.47%
Total Long-Term Liabilities $767.0K $35.70M $1.847M
YoY Change -58.47%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.77M $13.41M $12.85M
Total Long-Term Liabilities $767.0K $35.70M $1.847M
Total Liabilities $41.43M $49.18M $41.68M
YoY Change -0.62%
SHAREHOLDERS EQUITY
Retained Earnings -$60.42M -$53.54M -$43.01M
YoY Change 40.47%
Common Stock $36.00K $0.00 $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $62.09M -$51.15M -$41.49M
YoY Change
Total Liabilities & Shareholders Equity $103.5M $40.72M $42.88M
YoY Change 141.41%

Cashflow Statement

Concept 2012 Q4 2012 Q3 2011 Q4
OPERATING ACTIVITIES
Net Income -$6.876M -$5.685M -$2.015M
YoY Change 241.24% 444.02%
Depreciation, Depletion And Amortization $280.0K $260.0K $250.0K
YoY Change 12.0% 13.04%
Cash From Operating Activities $850.0K $230.0K -$5.480M
YoY Change -115.51% -87.57%
INVESTING ACTIVITIES
Capital Expenditures -$430.0K $10.00K -$250.0K
YoY Change 72.0%
Acquisitions
YoY Change
Other Investing Activities -$44.31M $8.500M $4.390M
YoY Change -1109.34% -240.96%
Cash From Investing Activities -$44.73M $8.510M $4.120M
YoY Change -1185.68% -241.36%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $70.00M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 67.01M 3.760M -80.00K
YoY Change -83862.5% -3860.0%
NET CHANGE
Cash From Operating Activities 850.0K 230.0K -5.480M
Cash From Investing Activities -44.73M 8.510M 4.120M
Cash From Financing Activities 67.01M 3.760M -80.00K
Net Change In Cash 23.13M 12.50M -1.440M
YoY Change -1706.25% -392.74%
FREE CASH FLOW
Cash From Operating Activities $850.0K $230.0K -$5.480M
Capital Expenditures -$430.0K $10.00K -$250.0K
Free Cash Flow $1.280M $220.0K -$5.230M
YoY Change -124.47% -88.11%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2012Q3 us-gaap Convertible Debt
ConvertibleDebt
6700000
CY2012Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
35829029 shares
CY2011Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10618000
CY2012Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
38600000 shares
CY2012Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-23000
CY2012Q3 us-gaap Liabilities Current
LiabilitiesCurrent
13407000
CY2012Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
466000
CY2012Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
10593000
CY2012Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-53543000
CY2012Q3 us-gaap Assets
Assets
40723000
CY2012Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17426000
CY2012Q3 us-gaap Short Term Investments
ShortTermInvestments
13467000
CY2012Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1124000
CY2012Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
5000000
CY2012Q3 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
10000000
CY2012Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2096000
CY2012Q3 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
4.00
CY2012Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
40723000
CY2012Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
425092 shares
CY2012Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
17830418 shares
CY2012Q3 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
7100000
CY2012Q3 us-gaap Common Stock Value
CommonStockValue
CY2012Q3 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
501000
CY2012Q3 us-gaap Liabilities
Liabilities
49180000
CY2012Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3144000
CY2012Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
153184 shares
CY2012Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
16602000
CY2012Q3 us-gaap Assets Current
AssetsCurrent
34359000
CY2012Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2418000
CY2012Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2012Q3 us-gaap Stockholders Equity
StockholdersEquity
-51148000
CY2012Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
649000
CY2012Q3 rgls Fair Value Assets Measured On Recurring Basis
FairValueAssetsMeasuredOnRecurringBasis
29092
CY2012Q3 rgls Fair Value Liabilities Measured On Recurring Basis
FairValueLiabilitiesMeasuredOnRecurringBasis
7069000
CY2012Q3 rgls Estimated Change In Fair Value
EstimatedChangeInFairValue
13467000
CY2012Q3 rgls Contract Receivable Net Current
ContractReceivableNetCurrent
3000000
CY2012Q3 rgls Investments Amortized Cost
InvestmentsAmortizedCost
13462000
CY2012Q3 rgls Accrued Interest Payable
AccruedInterestPayable
1227000
CY2012Q3 rgls Accrued Expense
AccruedExpense
1077000
CY2012Q3 rgls Accrued Payroll
AccruedPayroll
973000
CY2012Q3 rgls Convertible Notes Payable Fair Value Disclosure
ConvertibleNotesPayableFairValueDisclosure
7069000
CY2012Q3 rgls Other Long Term Obligations Excluding Current Portion
OtherLongTermObligationsExcludingCurrentPortion
374000
CY2012Q3 rgls Other Obligations Current
OtherObligationsCurrent
115000
CY2012Q3 rgls Common Stock Reserved For Future Issuance
CommonStockReservedForFutureIssuance
5630419 shares
CY2010Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21268000
CY2011Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
38600000 shares
CY2011Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-67000
CY2011Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12850000
CY2011Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
522000
CY2011Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
10735000
CY2011Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-43011000
CY2011Q4 us-gaap Assets
Assets
42881000
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9175000
CY2011Q4 us-gaap Short Term Investments
ShortTermInvestments
28969000
CY2011Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
10000000
CY2011Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
125000
CY2011Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
42881000
CY2011Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
425092 shares
CY2011Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
17233012 shares
CY2011Q4 us-gaap Common Stock Value
CommonStockValue
CY2011Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
446000
CY2011Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
206000
CY2011Q4 us-gaap Liabilities
Liabilities
41684000
CY2011Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
980000
CY2011Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3110000
CY2011Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
153184 shares
CY2011Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
16987000
CY2011Q4 us-gaap Assets Current
AssetsCurrent
38666000
CY2011Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1584000
CY2011Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
-41494000
CY2011Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
501000
CY2011Q4 rgls Fair Value Assets Measured On Recurring Basis
FairValueAssetsMeasuredOnRecurringBasis
37047000
CY2011Q4 rgls Estimated Change In Fair Value
EstimatedChangeInFairValue
28969000
CY2011Q4 rgls Investments Amortized Cost
InvestmentsAmortizedCost
29036000
CY2011Q4 rgls Accrued Interest Payable
AccruedInterestPayable
963000
CY2011Q4 rgls Accrued Expense
AccruedExpense
360000
CY2011Q4 rgls Accrued Payroll
AccruedPayroll
671000
CY2011Q4 rgls Other Long Term Obligations Excluding Current Portion
OtherLongTermObligationsExcludingCurrentPortion
438000
CY2011Q4 rgls Other Obligations Current
OtherObligationsCurrent
377000
CY2012Q3 us-gaap Fair Value Assumptions Weighted Average Volatility Rate
FairValueAssumptionsWeightedAverageVolatilityRate
0.75 pure
CY2012Q3 us-gaap Fair Value Inputs Entity Credit Risk
FairValueInputsEntityCreditRisk
0.110 pure
CY2012Q3 rgls Fair Value Assumption Estimate Weighted Average Public Offering Rate
FairValueAssumptionEstimateWeightedAveragePublicOfferingRate
0.90 pure
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
656000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
38000
us-gaap Profit Loss
ProfitLoss
-5587000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-76.97
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-803000
us-gaap Investment Income Interest
InvestmentIncomeInterest
96000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12823000
us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
81000
us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
11000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-4910000
us-gaap Interest Paid
InterestPaid
51000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
72588 shares
us-gaap Share Based Compensation
ShareBasedCompensation
609000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-10650000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
122000
us-gaap Operating Income Loss
OperatingIncomeLoss
-5261000
us-gaap Net Income Loss
NetIncomeLoss
-5587000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.024 pure
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2864000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-269000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.728 pure
us-gaap Gain Loss On Investments
GainLossOnInvestments
1000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5682000
us-gaap Repayments Of Other Long Term Debt
RepaymentsOfOtherLongTermDebt
307000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
117000
us-gaap Increase Decrease In Accrued Salaries
IncreaseDecreaseInAccruedSalaries
-318000
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
242000
us-gaap Operating Expenses
OperatingExpenses
15687000
us-gaap Revenues
Revenues
10426000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
131000
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
44140000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-95000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
237000
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
10426000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
609000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5456000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15864284 shares
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
44584000
us-gaap Interest Expense
InterestExpense
293000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
130000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-609000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9578000
rgls Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
103000
rgls Net Amortization Of Premiums On Investment Securities
NetAmortizationOfPremiumsOnInvestmentSecurities
401000
rgls Increase Decrease In Accrued Expenses
IncreaseDecreaseInAccruedExpenses
-258000
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2012
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2012-09-30
dei Entity Central Index Key
EntityCentralIndexKey
0001505512
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Trading Symbol
TradingSymbol
RGLS
dei Entity Registrant Name
EntityRegistrantName
REGULUS THERAPEUTICS INC.
dei Amendment Flag
AmendmentFlag
false
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
741000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
102000
us-gaap Profit Loss
ProfitLoss
-10532000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-41.03
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
14354000
us-gaap Investment Income Interest
InvestmentIncomeInterest
74000
us-gaap Income Taxes Paid
IncomeTaxesPaid
207000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14735000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-527000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1307000
us-gaap Interest Paid
InterestPaid
32000
us-gaap Unrealized Gain On Securities
UnrealizedGainOnSecurities
6000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
256682 shares
us-gaap Fair Value Assumptions Weighted Average Volatility Rate
FairValueAssumptionsWeightedAverageVolatilityRate
0.75 pure
us-gaap Share Based Compensation
ShareBasedCompensation
732000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
8251000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
185000
us-gaap Operating Income Loss
OperatingIncomeLoss
-8271000
us-gaap Net Income Loss
NetIncomeLoss
-10532000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.011 pure
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2998000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3469000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.710 pure
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10488000
us-gaap Unrealized Loss On Securities
UnrealizedLossOnSecurities
-1000
us-gaap Repayments Of Other Long Term Debt
RepaymentsOfOtherLongTermDebt
326000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-56000
us-gaap Increase Decrease In Accrued Salaries
IncreaseDecreaseInAccruedSalaries
302000
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
263000
us-gaap Operating Expenses
OperatingExpenses
17733000
us-gaap Revenues
Revenues
9462000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-28000
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
24550000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
44000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
724000
us-gaap Increase Decrease In Contract Receivables Net
IncreaseDecreaseInContractReceivablesNet
3000000
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
9462000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
732000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10560000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16523462 shares
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
9287000
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Use of Estimates</b></font></p> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">Our unaudited condensed financial statements are prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP). The preparation of our financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our financial statements and accompanying notes. Our most significant estimates relate to revenue recognition and stock-based compensation. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ from these estimates and assumptions.</font></p> </div>
us-gaap Fair Value Inputs Entity Credit Risk
FairValueInputsEntityCreditRisk
0.105 pure
us-gaap Interest Expense
InterestExpense
294000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-234000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1738000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
148000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9572000
rgls Convertible Senior Notes Maturity Date
ConvertibleSeniorNotesMaturityDate
February 2013
rgls Initial Public Offering Completion Date
InitialPublicOfferingCompletionDate
October 2012
rgls Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
55000
rgls Debt Instruments Amendment Date
DebtInstrumentsAmendmentDate
July 2012
rgls Net Amortization Of Premiums On Investment Securities
NetAmortizationOfPremiumsOnInvestmentSecurities
311000
rgls Net Proceeds From Issuance Of Convertible Notes Payable
NetProceedsFromIssuanceOfConvertibleNotesPayable
-5000000
rgls Conversion Of Debt To Common Stock
ConversionOfDebtToCommonStock
1256232
rgls Increase Decrease In Accrued Expenses
IncreaseDecreaseInAccruedExpenses
44000
rgls Proceeds From Issuance Of Convertible Promissory Notes And Warrants
ProceedsFromIssuanceOfConvertiblePromissoryNotesAndWarrants
5000000
rgls Accrued Interest Rate Percentage
AccruedInterestRatePercentage
0.03250 pure
rgls Amounts Accrued For Patent Expenditures
AmountsAccruedForPatentExpenditures
10000
rgls Interest Expense On Promissory Notes
InterestExpenseOnPromissoryNotes
25000
rgls Gain Loss From Valuation Of Convertible Note Payable
GainLossFromValuationOfConvertibleNotePayable
-331000
rgls Fair Value Assumption Estimate Weighted Average Public Offering Rate
FairValueAssumptionEstimateWeightedAveragePublicOfferingRate
0.90 pure
CY2011 us-gaap Unrealized Gain On Securities
UnrealizedGainOnSecurities
8000
CY2011 us-gaap Unrealized Loss On Securities
UnrealizedLossOnSecurities
-75000
CY2011Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1000
CY2011Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-11.68
CY2011Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
28000
CY2011Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3875000
CY2011Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
CY2011Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
89438 shares
CY2011Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-973000
CY2011Q3 us-gaap Net Income Loss
NetIncomeLoss
-1045000
CY2011Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.012 pure
CY2011Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
907000
CY2011Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.776 pure
CY2011Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1121000
CY2011Q3 us-gaap Operating Expenses
OperatingExpenses
4782000
CY2011Q3 us-gaap Revenues
Revenues
3809000
CY2011Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4000
CY2011Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-76000
CY2011Q3 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
3809000
CY2011Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
196000
CY2011Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1041000
CY2011Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15728852 shares
CY2011Q3 us-gaap Interest Expense
InterestExpense
97000
CY2011Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
CY2012Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-15.98
CY2012Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
20000
CY2012Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P0Y
CY2012Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
355735 shares
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.000 pure
CY2012Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5248000
CY2012Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1093000
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.000 pure
CY2012Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5675000
CY2012Q3 us-gaap Operating Expenses
OperatingExpenses
6341000
CY2012Q3 us-gaap Revenues
Revenues
2809000
CY2012Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3532000
CY2012Q3 us-gaap Net Income Loss
NetIncomeLoss
-5685000
CY2012Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-6000
CY2012Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
10000
CY2012Q3 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
2809000
CY2012Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
414000
CY2012Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5691000
CY2012Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16545674 shares
CY2012Q3 us-gaap Interest Expense
InterestExpense
110000
CY2012Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1738000
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
CY2012Q3 rgls Gain Loss From Valuation Of Convertible Note Payable
GainLossFromValuationOfConvertibleNotePayable
-331000

Files In Submission

Name View Source Status
0001193125-12-475602-index-headers.html Edgar Link pending
0001193125-12-475602-index.html Edgar Link pending
0001193125-12-475602.txt Edgar Link pending
0001193125-12-475602-xbrl.zip Edgar Link pending
d415954d10q.htm Edgar Link pending
d415954dex311.htm Edgar Link pending
d415954dex312.htm Edgar Link pending
d415954dex321.htm Edgar Link pending
d415954dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rgls-20120930.xml Edgar Link completed
rgls-20120930.xsd Edgar Link pending
rgls-20120930_cal.xml Edgar Link unprocessable
rgls-20120930_def.xml Edgar Link unprocessable
rgls-20120930_lab.xml Edgar Link unprocessable
rgls-20120930_pre.xml Edgar Link unprocessable
Show.js Edgar Link pending